ReviewClinical and vaccine immunology : CVI2015
New Approaches for Immunization and Therapy against Human Metapneumovirus.
Review in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study.The Lancet. Global health · 2021Pooled it
- Evaluation of a Live Attenuated Human Metapneumovirus Vaccine in Adults and Children.Journal of the Pediatric Infectious Diseases Society · 2018Trial
- Epidemiology, Genomic Diversity, and Evolutionary Dynamics of Human Metapneumovirus Over 7 Years of Integrated Community- and Hospital-Based Sentinel Surveillance in Senegal, 2018-2024.Influenza and other respiratory viruses · 2026Article
- Disease Spectrum of Human Metapneumovirus Infections in Infants and Young Children: Data From a Prospective Multicenter Study in Germany.The Pediatric infectious disease journal · 2026Article
- Human Metapneumovirus (HMPV): Advances in Diagnosis, Molecular Epidemiology, and Clinical Impact of an Underrecognized Respiratory Virus.Diagnostics (Basel, Switzerland) · 2026Review
- Small Molecule Inhibition of Mononegavirales RNA Polymerases.Journal of medical virology · 2026Review
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Development of a potent monoclonal antibody for treatment of human metapneumovirus infections.Nature communications · 2026Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
- Cangrelor and AVN-944 as repurposable candidate drugs for hMPV: analysis entailed by AI-driven in silico approach.Molecular diversity · 2025Article
- Interplay between endogenous hormones and immune systems in human metapneumovirus pathogenesis and management.Frontiers in pharmacology · 2025Review
- Cross-protective antibodies against common endemic respiratory viruses.Nature communications · 2023Article
- Profiling of hMPV F-specific antibodies isolated from human memory B cells.Nature communications · 2022Article
- Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.Journal of virology · 2020Article
- Review
- Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients.Frontiers in microbiology · 2018Review
- Article
- Severe Respiratory Viral Infections: New Evidence and Changing Paradigms.Infectious disease clinics of North America · 2017Review
- Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation.PLoS pathogens · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Human metapneumovirus (HMPV) is a paramyxovirus discovered in 2001 in the Netherlands. Studies have identified HMPV as an important causative agent of acute respiratory disease in infants, the elderly, and immunocompromised individuals. Clinical signs of infection range from mild upper respiratory illness to more serious lower respiratory illness, including bronchiolitis and pneumonia. There are currently no licensed therapeutics or vaccines against HMPV. However, several research groups have tested vaccine candidates and monoclonal antibodies in various animal models. Several of these approaches have shown promise in animal models. This minireview summarizes the current therapies used to treat HMPV infection as well as different approaches for immunization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.